Combo therapy does not affect COPD death rate, but improves breathing, report finds

Share this article:

The use of a steroid-plus-bronchodilator won't lower the death risk for patients with chronic obstructive pulmonary disease, but it will likely improve quality of life, according to new research results.

There was no notable difference in the mortality of COPD suffers who used Advair, an inhaled steroid combined with a long-acting bronchodilator, versus those given a placebo, according to researchers at the University of Liverpool and University Hospital Aintree. But researchers who studied more than 6,100 people with the condition noticed a 25% decline in breathing and health problems associated with the progressive, debilitating lung disease.

Study participants were randomly assigned the use of the long-acting bronchodilator salmeterol alone, the inhaled steroid fluticasone propionate alone, salmeterol plus fluticasone in combination (sold as Advair), or a placebo.

The full study appears in the New England Journal of Medicine.
Share this article:

More in News

Antipsychotics reduction goal raised to 30% by end of 2016, CMS and provider groups announce

Antipsychotics reduction goal raised to 30% by end ...

Long-term care providers are being asked to reduce the use of antipsychotic medications among residents by 25% by the end of 2015, and 30% by the end of 2016. Providers ...

CDC issues new guidelines on pneumococcal vaccine, says LTC flu vaccination rates remain low

CDC issues new guidelines on pneumococcal vaccine, says ...

Long-term care workers continued to have low rates of flu vaccination last season, despite there being 92% vaccination coverage overall among physicians and nurses, the Centers for Disease Control and ...

AL operators accused of withholding $2M in unpaid overtime, minimum wages ...

Four California assisted living operators are facing eight felony charges related to wage theft, tax and insurance violations, according to local reports.